{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:32:21Z","timestamp":1790253141563,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpba.2025.117094","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:13:16Z","timestamp":1754579596000},"page":"117094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Characterization of the glycosylation profile of erythropoiesis-stimulating agents (ESAs) and impact on potency"],"prefix":"10.1016","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9057-4428","authenticated-orcid":false,"given":"Julie","family":"TerWee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Bernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaila","family":"Wilson-Landy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Billingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3913-5848","authenticated-orcid":false,"given":"Krishana","family":"Gulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Srebalus Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jpba.2025.117094_bib1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/nbt1252","article-title":"Post-translational modifications in the context of therapeutic proteins","volume":"24","author":"Walsh","year":"2006","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.jpba.2025.117094_bib2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.xphs.2018.11.029","article-title":"The mechanistic impact of N-Glycosylation on stability, pharmacokinetics, and immunogenicity of therapeutic proteins","volume":"108","author":"Zhou","year":"2019","journal-title":"J. Pharm. Sci."},{"issue":"5-6","key":"10.1016\/j.jpba.2025.117094_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1034\/j.1600-0609.2002.02813.x","article-title":"The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhepo and NESP","volume":"69","author":"Jelkmann","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jpba.2025.117094_bib4","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.3389\/fchem.2022.863118","article-title":"Strategies for glycoengineering therapeutic proteins","volume":"10","author":"Dammen-Brower","year":"2022","journal-title":"Front. Chem."},{"issue":"5561","key":"10.1016\/j.jpba.2025.117094_bib5","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1126\/science.1069540","article-title":"Mannose receptor-mediated regulation of serum glycoprotein homeostasis","volume":"295","author":"Lee","year":"2002","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jpba.2025.117094_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/glycob\/cwm017","article-title":"Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys","volume":"17","author":"Jones","year":"2007","journal-title":"Glycobiology"},{"issue":"17","key":"10.1016\/j.jpba.2025.117094_bib7","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1016\/S0021-9258(19)63808-1","article-title":"Physical and chemical studies on ceruloplasmin: IX. The role of galactosyl residues in the clearance of ceruloplasmin from the circulation","volume":"245","author":"van den Hamer","year":"1970","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jpba.2025.117094_bib8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.bi.51.070182.002531","article-title":"Carbohydrate-specific receptors of the liver","volume":"51","author":"Ashwell","year":"1982","journal-title":"Annu Rev. Biochem"},{"issue":"5","key":"10.1016\/j.jpba.2025.117094_bib9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000356193","article-title":"Physiology and pharmacology of erythropoietin","volume":"40","author":"Jelkmann","year":"2013","journal-title":"Transfus. Med. Hemother."},{"issue":"25","key":"10.1016\/j.jpba.2025.117094_bib10","doi-asserted-by":"crossref","first-page":"12059","DOI":"10.1016\/S0021-9258(18)45317-3","article-title":"Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA","volume":"262","author":"Sasaki","year":"1987","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.jpba.2025.117094_bib11","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1021\/bi00415a038","article-title":"Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins","volume":"27","author":"Tsuda","year":"1988","journal-title":"Biochemistry"},{"key":"10.1016\/j.jpba.2025.117094_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.aca.2011.10.028","article-title":"Analysis of recombinant human erythropoietin glycopeptides by capillary electrophoresis electrospray\u2013time of flight-mass spectrometry","volume":"709","author":"Gim\u00e9nez","year":"2012","journal-title":"Anal. Chim. Acta"},{"issue":"8","key":"10.1016\/j.jpba.2025.117094_bib13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nbt.1651","article-title":"Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins","volume":"28","author":"Ghaderi","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.jpba.2025.117094_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood.V73.1.84.84","article-title":"Survival of recombinant erythropoietin in the circulation: the role of carbohydrates","volume":"73","author":"Fukuda","year":"1989","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jpba.2025.117094_bib15","doi-asserted-by":"crossref","first-page":"7819","DOI":"10.1073\/pnas.86.20.7819","article-title":"Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells","volume":"86","author":"Takeuchi","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"13","key":"10.1016\/j.jpba.2025.117094_bib16","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1016\/S0021-9258(19)42503-9","article-title":"On the mechanism of Erythropoietin-induced differentiation: XIII. The role of sialic acid in erythropoietin action","volume":"249","author":"Goldwasser","year":"1974","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jpba.2025.117094_bib17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0301-472X(03)00006-7","article-title":"Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin","volume":"31","author":"Egrie","year":"2003","journal-title":"Exp. Hematol."},{"issue":"12","key":"10.1016\/j.jpba.2025.117094_bib18","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.exphem.2004.08.004","article-title":"Control of rHuEPO biological activity: the role of carbohydrate","volume":"32","author":"Elliott","year":"2004","journal-title":"Exp. Hematol."},{"issue":"9","key":"10.1016\/j.jpba.2025.117094_bib19","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1248\/bpb.33.1596","article-title":"Measurement of sialic acid content is insufficient to assess bioactivity of recombinant human erythropoietin","volume":"33","author":"Yanagihara","year":"2010","journal-title":"Biol. Pharm. Bull."},{"issue":"8","key":"10.1016\/j.jpba.2025.117094_bib20","doi-asserted-by":"crossref","first-page":"e1418","DOI":"10.1002\/onco.13713","article-title":"The first 2 years of biosimilar epoetin for cancer and chemotherapy-induced anemia in the U.S.: a review from the Southern network on adverse reactions","volume":"26","author":"Bennett","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jpba.2025.117094_bib21","unstructured":"U.S. Food and Drug Administration. FDA Briefing Document Oncologic Drugs Advisory Committee Meeting May 25, 2017 BLA 125545 \u201cEpoetin Hospira\u201d, a proposed biosimilar to Epogen\/Procrit (epoetin alfa) Applicant: Hospira Inc., a Pfizer Company. \u3008https:\/\/www.fda.gov\/media\/105378\/download\u3009 accessed 31 July 2025."},{"issue":"13","key":"10.1016\/j.jpba.2025.117094_bib22","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/elps.200600075","article-title":"Glycoform characterization of erythropoietin combining glycan and intact protein analysis by capillary electrophoresis \u2013 electrospray \u2013 time-of-flight mass spectrometry","volume":"27","author":"Balaguer","year":"2006","journal-title":"Electrophoresis"},{"issue":"2020","key":"10.1016\/j.jpba.2025.117094_bib23","article-title":"Glycan analysis of erythropoiesis-stimulating agents","volume":"180","author":"Cowper","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.jpba.2025.117094_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/bjoc.2001.1746","article-title":"Development and characterization of novel erythropoiesis stimulating protein (NESP)","volume":"84","author":"Egrie","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jpba.2025.117094_bib25","unstructured":"US Patent 5,856,298 US5856298A - Erythropoietin isoforms - Google Patents \u3008https:\/\/patents.google.com\/patent\/US5856298A\/en\u3009, accessed 14 Jan 2025."},{"key":"10.1016\/j.jpba.2025.117094_bib26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/BF01053197","article-title":"Biological and physicochemical characterization of recombinant human erythropoietins fractionated by mono q column chromatography and their modification with sialytransferase","volume":"13","author":"Morimoto","year":"1996","journal-title":"Glycoconj. J."},{"issue":"1","key":"10.1016\/j.jpba.2025.117094_bib27","first-page":"109","article-title":"Chromatographic separation of recombinant human erythropoietin isoforms","volume":"791","author":"Gokana","year":"1997","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.jpba.2025.117094_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114757","article-title":"Enhancing pharmacokinetic and pharmacodynamic properties of recombinant therapeutic proteins by manipulation of sialic acid content","volume":"163","author":"Chia","year":"2023","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.jpba.2025.117094_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jpba.2018.02.043","article-title":"Comprehensive glycan analysis of twelve recombinant human erythropoietin preparations for manufacturers in China and Japan","volume":"153","author":"Cowper","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.117094_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12257-021-0042-0","article-title":"Differences in proportion of N-acetyllactosamine and O-acetylated sialic acid have no significant effect on the pharmacokinetics and biological activity of darbopoetin alfa","volume":"27","author":"Lee","year":"2002","journal-title":"Biotechnol. Bioprocess Eng."},{"issue":"5","key":"10.1016\/j.jpba.2025.117094_bib31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/glycob\/10.5.511","article-title":"Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoid cell line does not alter its biological properties","volume":"10","author":"Cointe","year":"2020","journal-title":"Glycobiology"},{"key":"10.1016\/j.jpba.2025.117094_bib32","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.xphs.2018.01.018","article-title":"Structure-function relationships for recombinant erythropoietins: a case study from a proposed manufacturing change with implications for erythropoietin biosimilar study designs","volume":"107","author":"Grampp","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jpba.2025.117094_bib33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.biologicals.2005.05.001","article-title":"A sialylation-sensitive cell-based in vitro bioassay for erythropoietin; incorporation of the galactose-binding erythrina crista-galli lectin","volume":"33","author":"Liefooghe","year":"2005","journal-title":"Biologicals"},{"issue":"49","key":"10.1016\/j.jpba.2025.117094_bib34","doi-asserted-by":"crossref","first-page":"14524","DOI":"10.1021\/bi0265022","article-title":"Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions","volume":"41","author":"Darling","year":"2002","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.jpba.2025.117094_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231830","article-title":"Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa","volume":"15","author":"Tani","year":"2020","journal-title":"PLoS One"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525004352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525004352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T02:41:41Z","timestamp":1757126501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525004352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"alternative-id":["S0731708525004352"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117094","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the glycosylation profile of erythropoiesis-stimulating agents (ESAs) and impact on potency","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117094"}}